In a filing, Bio Green Med Solution Inc revealed its 10% Owner Yap Kim Choy unloaded Company’s shares for reported $0.2 million on Oct 29 ’25. In the deal valued at $1.83 per share,110,749 shares were sold. As a result of this transaction, Yap Kim Choy now holds 140,760 shares worth roughly $0.25 million.
Then, Yap Kim Choy sold 13,111 shares, generating $23,967 in total proceeds. Upon selling the shares at $1.83, the 10% Owner now owns 251,509 shares.
Before that, Yap Kim Choy sold 120,250 shares. Bio Green Med Solution Inc shares valued at $254,690 were divested by the 10% Owner at a price of $2.12 per share. As a result of the transaction, Yap Kim Choy now holds 264,620 shares, worth roughly $0.47 million.
Ladenburg Thalmann began covering BGMS with “Buy” recommendation on September 07, 2018. H.C. Wainwright started covering the stock on October 16, 2015. It rated BGMS as “a Buy”.
Price Performance Review of BGMS
On Friday, Bio Green Med Solution Inc [NASDAQ:BGMS] saw its stock fall -2.20% to $1.78. Over the last five days, the stock has lost -3.26%. Bio Green Med Solution Inc shares have fallen nearly -98.91% since the year began. Nevertheless, the stocks have fallen -98.03% over the past one year. While a 52-week high of $213.60 was reached on 01/03/25, a 52-week low of $1.70 was recorded on 10/31/25.
Levels Of Support And Resistance For BGMS Stock
The 24-hour chart illustrates a support level at 1.6433, which if violated will result in even more drops to 1.5067. On the upside, there is a resistance level at 1.8833. A further resistance level may holdings at 1.9867.
How much short interest is there in Bio Green Med Solution Inc?
A steep rise in short interest was recorded in Bio Green Med Solution Inc stocks on 2025-10-15, growing by 68078.0 shares to a total of 0.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 45677.0 shares. There was a rise of 59.85%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 04, 2010 when Roth Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
